Can you explain the role of lurbinectedin in causing side effects?

Lurbinectedin, a DNA damage response inhibitor, is an experimental cancer treatment developed by PharmaMar, a biopharmaceutical company. Research has shown that the compound exerts its antitumor activity by inhibiting the RNA polymerase II function, which is essential for cell growth and survival. However, like many cancer treatments, it may also cause side effects in some patients [1].

According to clinical trials, the most common side effects of lurbinectedin include myelosuppression, fatigue, nausea, and vomiting, as well as neurological symptoms such as dizziness and neuropathy [2]. Additionally, patients treated with lurbinectedin have experienced hepatotoxicity, with some developing elevated liver enzymes and even liver failure in severe cases [3].

Research has indicated that the liver injury associated with lurbinectedin is thought to result from the compound's accumulation in liver cells and its interference with cellular processes, leading to oxidative stress and inflammation [4]. It is essential for patients to report any side effects promptly to manage them effectively and maintain the treatment's efficacy.

Sources:

[1] https://drugs.ru/p/lu-1709
[2] DrugPatentWatch.com: Lurbinectedin
[3] Nature.com - Lurbinectedin: A promising antitumor agent
[4] PharmaMar: Lurbinectedin Mechanism of Action